TABLE 1.
Binding kinetics and affinity of isatuximab and daratumumab with rhCD38 and CD38‐expressing MM cells
| Method | Neg control | Anti‐CD38 mAb | Sample | K a (M−1s−1) | K d (s−1) | K D (M) |
|---|---|---|---|---|---|---|
| SPR | hIgG1 isotype | Isatuximab | rhCD38 | 1.14E+06 | 3.06E−04 | 3.12E−10 |
| rhCD38/ara‐F‐NAD inhibitor | 1.36E+06 | 4.30E−05 | 3.16E−11 | |||
| rhCD38/HB‐7 | 3.32E+05 | <1.0E−06 | <3.01E−12 | |||
| Daratumumab | rhCD38 | 8.80E+04 | 8.41E−04 | 9.56E−09 | ||
| LT | Parental JJN3 | Isatuximab | JJN3.CD38 | 1.23E+05 | 4.19E−05 | 3.40E−10 |
| Daratumumab | 1.29E+05 | 4.73E−05 | 3.67E−10 |
Abbreviations: ara‐F‐NAD, ara‐F‐nicotinamide adenine dinucleotide; hIgG1, human immunoglobulin G1; ka, association rate constant; kd, dissociation rate constant; K D, equilibrium dissociation constant; LT, LigandTracer; M, molar; mAb, monoclonal antibody; neg, negative; rhCD38, recombinant human CD38; s, seconds, SPR, surface plasmon resonance.